PCI Biotech Holding Logo

PCI Biotech Holding

Biopharma firm evaluating its future after discontinuing its core technology development.

PCIB | OL

Overview

Corporate Details

ISIN(s):
NO0010405640
LEI:
5967007LIEEXZXFIGG77
Country:
Norway
Address:
Ullernchausséen 64, 0379 OSLO
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

PCI Biotech Holding is a biopharmaceutical company that was focused on developing a proprietary photochemical technology platform. This platform was designed to enhance intracellular drug delivery for therapeutic applications, including immunotherapy and dermatology, and to advance the bioprocessing and manufacturing of viral vectors for gene therapy. In August 2025, the company announced the discontinuation of its core technology development. Consequently, PCI Biotech is currently evaluating its future operations and strategic direction.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-25 15:36
Business and Financial Review
PCI Biotech update on future operations
English 3.6 KB
2025-08-26 16:14
Report Publication Announcement
PCI Biotech: Invitation to first half 2025 results presentation and corporate u…
English 2.3 KB
2025-08-22 14:15
Major Shareholding Notification
Flaggemelding
Norwegian 411 bytes
2025-08-22 11:09
Major Shareholding Notification
Flaggemelding
Norwegian 451 bytes
2025-08-18 20:39
Regulatory News Service
PCI Biotech announces discontinuation of development of the PCL technology and …
English 3.4 KB
2025-05-22 09:45
Post-Annual General Meeting Information
PCI Biotech: Minutes of Annual General Meeting 2025
Norwegian 449.8 KB
2025-05-22 09:45
Post-Annual General Meeting Information
PCI Biotech: Minutes of Annual General Meeting 2025
English 866 bytes
2025-05-20 20:08
Declaration of Voting Results & Voting Rights Announcements
PCI BIotech: Disclosure of voting rights for Chair of the Board
English 1.2 KB
2025-04-30 08:00
Pre-Annual General Meeting Information
Notice of Annual General Meeting 2025
Norwegian 188.6 KB
2025-04-30 08:00
Pre-Annual General Meeting Information
Notice of Annual General Meeting 2025
Norwegian 146.9 KB
2025-04-30 08:00
Pre-Annual General Meeting Information
Notice of Annual General Meeting 2025
English 167.8 KB
2025-04-30 08:00
Pre-Annual General Meeting Information
Notice of Annual General Meeting 2025
English 208.0 KB
2025-04-30 08:00
Pre-Annual General Meeting Information
Notice of Annual General Meeting 2025
English 977 bytes
2025-04-24 15:30
Annual Report (ESEF)
PCI Biotech Holding ASA: Annual Report 2024
English 5.4 MB
2025-04-24 15:30
Annual Report
PCI Biotech Holding ASA: Annual Report 2024
English 1.2 MB

Automate Your Workflow. Get a real-time feed of all PCI Biotech Holding filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for PCI Biotech Holding via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Developing novel cancer immunotherapies, including peptide vaccines and iPS-NKT cell therapies.
Japan 4594
Brilliant Future AB Logo
A data-driven survey platform to measure and improve employee & customer experiences.
Sweden BRILL
b-style holdings,Inc. Logo
Offers flexible staffing for homemakers and specialized recruitment for skilled professionals.
Japan 302A
BTS Group Logo
Helps organizations execute strategy via experiential learning for leadership and sales teams.
Sweden BTS
B.U Technology Logo
Commercializes university research via IP management, licensing, and new venture creation.
South Korea 230980
Advancing high-grade copper and precious metal projects from discovery to production.
Canada N/A
Cantargia Logo
Develops antibody treatments targeting IL1RAP for cancer and autoimmune/inflammatory diseases.
Sweden CANTA
Captor Therapeutics S.A. Logo
Developing TPD therapeutics for oncology and autoimmune diseases with its Optigrade™ platform.
Poland CTX
Offers one-stop BPO, CRM, and staffing for admin, manufacturing, and logistics.
Japan 6070
Carna Biosciences, Inc. Logo
Develops kinase inhibitor drugs for oncology/autoimmune diseases & offers discovery support services.
Japan 4572

Talk to a Data Expert

Have a question? We'll get back to you promptly.